Could a new dosing schedule supercharge bone strength?

NCT ID NCT06059222

Recruiting now Disease control Sponsor: University of Aarhus Source: ClinicalTrials.gov ↗

First seen Jul 02, 2026 · Last updated Jul 02, 2026

Summary

This study looks at whether giving the osteoporosis drug romosozumab in two separate 6-month blocks, with breaks for another drug called zoledronate, can build more bone than the standard 12-month course. It involves 270 postmenopausal women with osteoporosis and a recent fracture. The goal is to find the safest and most effective way to combine these medications.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Romosozumab (Evenity) and zoledronate
What this could lead to: If successful, this could identify a more effective dosing schedule for romosozumab and zoledronate, leading to stronger bones and fewer fractures in women with osteoporosis.
What could go wrong: This is a phase 4 trial with 270 participants, so results may not apply to all patients. Different dosing schedules may not improve outcomes and could carry risks like bone pain or rare jaw problems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OSTEOPOROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

osteoporosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OSTEOPOROSIS

Contacts and locations

Locations

Department of Endrocinology and Internal Medicine
RECRUITING

Aarhus, 8000, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.